HLA-A*33-DR3 and A*33-DR9 Haplotypes Enhance the Risk of Type 1 Diabetes in Han Chinese
Overview
Authors
Affiliations
Aims/introduction: To investigate the typing for human leukocyte antigen (HLA) class I in Chinese patients with type 1 diabetes as a complement screening for HLA class II.
Materials And Methods: A total of 212 type 1 diabetic patients and 200 healthy controls were enrolled. The genetic polymorphisms of HLA class I and II were examined with a high-resolution polymerase chain reaction sequence-based typing method.
Results: The haplotype, A*33:03-B*58:01-C*03:02(A33), was associated with type 1 diabetes (P = 1.0 × 10(-4) , odds ratio 3.2 [1.738-5.843]). The A33-DR3 and A33-DR9 haplotypes significantly enhanced the risk of type 1 diabetes (A33-DR3, odds ratio 5.1 [2.40-10.78], P = 4.0 × 10(-6) ; A33-DR9, odds ratio 13.0 [1.69-100.32], P = 0.004). In type 1 diabetic patients, compared with A33-DR3-negative carriers, A33-DR3-positive carriers had significantly lower percentages of CD3(+) CD4(+) T cells (42.5 ± 7.72 vs 37.0 ± 8.35%, P = 0.023), higher percentages of CD3(+) CD8(+) T cells (27.4 ± 7.09 vs 32.8 ± 5.98%, P = 0.005) and T-cell receptor α/β T cells (70.0 ± 7.00 vs 73.6 ± 6.25%, P = 0.031), and lower CD4/CD8 ratios (1.71 ± 0.75 vs 1.16 ± 0.35, P = 0.003).
Conclusions: It is the first time that the haplotypes A33-DR3 and A33-DR9 were found with an enhanced predisposition to type 1 diabetes in Han Chinese. A33-DR3 was associated with a reduction in the helper-to-cytotoxic cell ratio and preferential increase of T-cell receptor α/β T cell. The typing for HLA class I and its immunogenetic effects are important for more accurate HLA class II haplotype risk prediction and etiology research in type 1 diabetic patients.
Mardi S, Rashidian M, Bastan F, Molaverdi G, Mozhgani S Virol J. 2025; 22(1):13.
PMID: 39833815 PMC: 11749399. DOI: 10.1186/s12985-024-02612-7.
The Association of Human Leukocyte Antigens Complex with Type 1 Diabetes in the Omani Population.
Al-Balushi M, Al-Badi S, Al-Yaarubi S, Al-Riyami H, Al-Shidhani A, Al-Hinai S Sultan Qaboos Univ Med J. 2023; 23(1):68-75.
PMID: 36865417 PMC: 9974035. DOI: 10.18295/squmj.2.2022.016.
Jiang Z, Ren W, Liang H, Yan J, Yang D, Luo S Diabetologia. 2021; 64(9):2026-2036.
PMID: 34023962 PMC: 8382651. DOI: 10.1007/s00125-021-05476-6.
Gaff J, Octaviana F, Pillay P, Ngassa Mbenda H, Ariyanto I, Gan J Int J Mol Sci. 2020; 21(2).
PMID: 31936167 PMC: 7014294. DOI: 10.3390/ijms21020380.
A pilot study of preproinsulin peptides reactivity in Chinese patients with type 1 diabetes.
Xian Y, Xu H, Gao Y, Yan J, Lv J, Ren W Diabetes Metab Res Rev. 2019; 36(2):e3228.
PMID: 31655017 PMC: 7027544. DOI: 10.1002/dmrr.3228.